Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + etoposide for relapsed or metastatic triple-negative breast cancer
ChiCTR1900024696Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and etoposide in triple-negative breast cancer (TNBC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: Lesion size and Objective response rate. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
anlotinibetoposide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1900024696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024696.